US 12,364,738 B2
Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
Wafi Siala, Woluwe St. Pierre (BE); and Thomas Vanzieleghem, Louvain-la-Neuve (BE)
Assigned to ONELIFE S.A., Louvain-la-Neuve (BE)
Appl. No. 16/308,261
Filed by ONELIFE S.A., Louvain-la-Neuve (BE)
PCT Filed Jun. 2, 2017, PCT No. PCT/EP2017/063533
§ 371(c)(1), (2) Date Dec. 7, 2018,
PCT Pub. No. WO2017/211737, PCT Pub. Date Dec. 14, 2017.
Claims priority of application No. 2016/5427 (BE), filed on Jun. 8, 2016; and application No. 16173468 (EP), filed on Jun. 8, 2016.
Prior Publication US 2019/0192639 A1, Jun. 27, 2019
Int. Cl. A61K 38/46 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 31/407 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/7036 (2006.01); A61K 38/43 (2006.01); A61K 38/47 (2006.01); A61K 45/06 (2006.01); A61L 27/54 (2006.01); A61L 29/16 (2006.01); A61L 31/16 (2006.01); A61P 31/04 (2006.01)
CPC A61K 38/465 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/407 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/7036 (2013.01); A61K 38/43 (2013.01); A61K 38/47 (2013.01); A61K 45/06 (2013.01); A61L 27/54 (2013.01); A61L 29/16 (2013.01); A61L 31/16 (2013.01); A61P 31/04 (2018.01); C12Y 301/21001 (2013.01); C12Y 302/01004 (2013.01); C12Y 302/01052 (2013.01); A61L 2300/404 (2013.01); Y02A 50/30 (2018.01)] 1 Claim
 
1. A method of treatment for post-implantation infections of mammalian bodies, the method comprising:
administering a therapeutically effective amount of a composition comprising a combination of an enzymatic cocktail of Dispersin B, cellulase, and DNase; and a fluoroquinolone microbicidal molecule, wherein the composition is sterile, and wherein the composition is effective to reduce by at least 1 Log 10 the number of viable bacteria in biofilms formed post-implantation by bacteria species selected from the species group consisting of Staphylococcus aureus to a mammalian body following implantation of an implantable medical device, the mammalian body being subject to post-implantation infection by bacteria belonging to the species Staphylococcus aureus.